Baseline characteristics in the collaborative atorvastatin. In summary, this trial supports the use of statin therapy to lower cholesterol levels patients with known coronary heart disease and ldl levels 125 mgdl. Aspenatorvastatin study for prevention of coronary heart disease endpoints in noninsulindependent. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes. Based on the clinical cards data, the favourable cost effectiveness of atorvastatin 10mg in. Colhoun hm, betteridge dj, durrington pn, hitman ga, neil ha, livingstone sj, charltonmenys. Atorvastatin, cardiovascular disease, cards, creactive protein, ldl cholesterol, statins, type 2 diabetes. The angloscandinavian cardiac outcomes trial lipid. Apolipoproteins, cardiovascular risk and statin response. Atorvastatin reduced major cardiovascular disease events. Other calculators combine a general and a diabetesspecific approach. Study comparing pitavastatin and atorvastatin in patients. The clinical benefit of use of statins in patients with type 2 diabetes has been demonstrated in several randomized, controlled trials, including the cards clinical trial. Pdf primary prevention of cardiovascular disease with.
A multicenter study in malaysia to determine the efficacy and safety of a generic atorvastatin n punithavathi, dch, l m ong, frcp, y l l lena, msc, s leekha, md, on behalf of the storvas clinical trial study group clinical research centre, penang hospital, residency road 10990 pulau pinang, malaysia, ranbaxy malaysia sdn bhd original. The reference model predicts life expectancy for diabetics. The diabetes atorvastatin lipid intervention dali study have reported that either 10 or 80 mg of atorvastatin is equally effective in the treatment of diabetic dyslipidemia 15. Pdf there are few data on the role of lipid lowering in the primary prevention of coronary. Esceas guidelines for the management of dyslipidemias. Highdose atorvastatin was linked to a 37 percent increased diabetes risk, the study found. One in 4 americans 40 years of age takes a statin to reduce the risk of. Collaborative atorvastatin diabetes study cards 2838 primary prevention patients no ascvd with type 2 diabetes at least 1 other cv risk factor such as smoking, hypertension, retinopathy, or microalbuminuria ldlc levels. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of preexisting vascular disease and who had only. A case report of dyslipidemia management in newonset type. Atorvastatin in patients with type 2 diabetes mellitus. The goal of the collaborative atorvastatin diabetes study cards trial was to determine the effectiveness of the lipidlowering agent atorvastatin in reducing cardiovascular events and death among diabetic patients with at least one heart disease risk factor, but without elevated cholesterol. Colhoun hm, betteridge dj, durrington pn, hitman ga, neil ha, livingstone sj, thomason mj, mackness mi, charltonmenys v, fuller jh 2004.
Al powers, director of the division of diabetes, endocrinology and metabolism at. Pdf design of the collaborative atorvastatin diabetes study. An overview of cards collaborative atorvastatin diabetes. Collaborative atorvastatin diabetes study american. The trial was stopped 2 years earlier than planned because of significant benefit at the second interim analysis. Should all diabetic patients be treated with a statin. It acts both by reducing the production of cholesterol and increasing its rate of removal from the body. Study cards, 2,838 subjects with type 2 diabetes who did not have established cardiovascular disease were randomly assigned to receive atorvastatin or placebo 11. We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of ldlcholesterol.
Statins and glycaemic control in individuals with diabetes. Ppt atorvastatin clinical study program powerpoint. Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipidlowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. These joint esceuropean atherosclerosis society eas guide lines on the. It is given by mouth to people who have hypercholesterolaemia high cholesterol levels in the blood. The collaborative atorvastatin diabetes study cards.
Baseline characteristics in the collaborative atorvastatin diabetes study cards in patients with type 2 diabetes. The care trial randomized 4,159 patients from 80 centres across canada and the united states. Effect of atorvastatin on creactive protein and benefits for. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of pre. An analysis based on the uk prospective diabetes study ukpds risk engine. July 21 issue 1 report a lack of benefit from therapy with 20 mg of atorvastatin among patients with type 2 diabetes mellitus who were receiving hemodialysis. This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Cards study design collaborative atorvastatin diabetes study. Cost effectiveness of atorvastatin in patients with type 2.
Based on these findings, physicians will have to weigh risks versus benefits before prescribing statins, said dr. The effects of lowering ldl cholesterol with statin therapy in people. The collaborative atorvastatin diabetes study cards is a multi. Abstract background there are few data on the role of lipid lowering in the primary prevention of coronary heart disease chd in diabetic. The minor increase in blood glucose with statins may be enough to push atrisk. Safety of atorvastatin in the collaborative atorvastatin. Costeffectiveness of primary prevention of cardiovascular. Combining ezetimibe with a statin reduces ldlc by an additional. Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus colhoun hm, betteridge dj, durrington pn, et al. Teaching and learning taught masters after you graduate taught masters download a prospectus taught masters admissions process taught masters fees for taught masters study. Atorvastatin, cardiovascular disease, cards, creactive protein, ldlcholesterol, statins, type 2 diabetes. Design of the collaborative atorvastatin diabetes study cards. The aim of the collaborative atorvastatin diabetes study cards was to assess the effectiveness of 10 mg of atorvastatin daily versus placebo in the primary prevention of cardiovascular disease in patients with type 2 diabetes.
Patients with type 2 diabetes mellitus have a high risk of developing cardiovascular cv disease. A justification for increased risk of diabetes mellitus melina sadighara1,2, zahra amirsheardost1, mohsen minaiyan 2, valiollah hajhashemi, parvaneh naserzadeh1, ahmad salimi1,3, enayatollah seydi1,4 and jalal pourahmad1 1department of pharmacology and toxicology, faculty of pharmacy, shahid beheshti university of medical sciences. An analysis from the collaborative atorvastatin diabetes study cards author links open overlay panel helen m. In a metaanalysis combining published data from 47 trials in 128 601. Patients with type 2 diabetes and no prior cvd n 2,838. Following study termination the data will be merged with. Combining ldlcholesterol and crp ontreatment categories. A landmark lipitor study of patients with type 2 diabetes. Register, 7 look ahead action for health in diabetes, 8 addition anglodanishdutch study of intensive treatment in people with screen detected diabetes in primary care, 9 cards collaborative atorvastatin diabetes study. Atorvastatin is a drug used to lower high levels of cholesterol and other fatlike substances in the blood. Safety of atorvastatin in the collaborative atorvastatin diabetes study cards the safety and efficacy of sta the safety and efficacy of statins for cvd prevention is well established, yet some physicians have concerns about the longterm safety of this class. The collaborative atorvastatin diabetes study cards randomized placebocontrolled trial.
Atorvastatin reduced cv events even in low ldl dm patients. Openurl1crossref2pubmed3web of science4 q in patients with type 2 diabetes mellitus, is atorvastatin better than. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes cards overview 1 a multicenter randomized placebo controlled trial to determine hard outcomes of atorvastatin 10mg vs. Atorvastatin in new onset type 1 diabetes mellitus t1dm. A multicenter study in malaysia to determine the efficacy. An overview of cards collaborative atorvastatin diabetes study primary prevention of cardiovascular disease with atorvastatin in type 2. The collaborative atorvastatin diabetes study cards is the only diabetesspecific primary prevention trial performed.
1546 806 513 274 1419 1480 347 253 1427 117 633 514 254 413 379 778 1124 188 620 1564 1546 1368 899 401 391 686 45 562 910 1210 813 934 1157 722 1192 261 720 1082 721 1443 1304 235 1184 1206 1229 1293